Back to School: How biopharma can reboot drug development. Access exclusive analysis here
OncoGenex said investigators at the Sarah Cannon Research Institute began the double-blind, U.S. Phase II Rainier trial to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury